Huiyuan Y. Li

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Reprogramming rather than depleting immunity: Targeting the CD38-NAD+ axis in antibody-mediated autoimmunity.

Reprogramming rather than depleting immunity: Targeting the CD38-NAD+ axis in antibody-mediated autoimmunity.

Journal: Clinical and translational medicine

Published: August 19, 2026

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Journal: Haematologica

Published: June 01, 2026

No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.

No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study.

Journal: Global medical genetics

Published: March 12, 2026

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: November 05, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: August 25, 2025

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

CDK8/CDK19 inhibition restores T-cell homeostasis in primary immune thrombocytopenia.

Journal: Blood

Published: August 21, 2025

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Journal: Nature medicine

Published: July 25, 2025

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 24, 2025

Identification of key biomarkers for initial corticosteroid resistance in newly diagnosed primary immune thrombocytopenia.

Identification of key biomarkers for initial corticosteroid resistance in newly diagnosed primary immune thrombocytopenia.

Journal: Experimental hematology

Published: May 01, 2025

Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization.

Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization.

Journal: BMC biotechnology

Published: March 07, 2025

Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.

Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.

Journal: Advances in therapy

Published: October 17, 2024

Showing 1-12 of 86

Last Updated: 09/26/2026